NYSE:BHVN - Biohaven Pharmaceutical Stock Price, Forecast & News

Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) announced its quarterly earnings results on Tuesday, February, 25th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.91) by $0.94. During the same quarter in the previous year, the business posted ($1.34) earnings per share. View Biohaven Pharmaceutical's Earnings History.

Biohaven Pharmaceutical is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Biohaven Pharmaceutical.

13 brokers have issued twelve-month target prices for Biohaven Pharmaceutical's shares. Their forecasts range from $50.00 to $100.00. On average, they anticipate Biohaven Pharmaceutical's stock price to reach $69.83 in the next twelve months. This suggests a possible upside of 64.3% from the stock's current price. View Analyst Price Targets for Biohaven Pharmaceutical.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biohaven Pharmaceutical.

News articles about BHVN stock have been trending very negative on Friday, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biohaven Pharmaceutical earned a news impact score of -3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Biohaven Pharmaceutical.

Biohaven Pharmaceutical saw a increase in short interest in February. As of February 14th, there was short interest totalling 7,970,000 shares, an increase of 23.0% from the January 30th total of 6,480,000 shares. Based on an average trading volume of 908,300 shares, the short-interest ratio is presently 8.8 days. Currently, 17.0% of the company's stock are sold short. View Biohaven Pharmaceutical's Current Options Chain.

Some companies that are related to Biohaven Pharmaceutical include Perrigo (PRGO), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), Amarin (AMRN), United Therapeutics (UTHR) and BridgeBio Pharma (BBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven Pharmaceutical investors own include AbbVie (ABBV), Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Netflix (NFLX), Sarepta Therapeutics (SRPT) and ACADIA Pharmaceuticals (ACAD).

(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Biohaven Pharmaceutical's stock is owned by many different of institutional and retail investors. Top institutional investors include Capital International Investors (5.59%), Oracle Investment Management Inc. (3.68%), State Street Corp (3.66%), Capital World Investors (3.15%), Capital International Inc. CA (2.18%) and Eagle Asset Management Inc. (1.43%). Company insiders that own Biohaven Pharmaceutical stock include Declan Doogan, Elyse Stock, Eric Aguiar, Gregory Bailey, James Engelhart, John Tilton, John W Childs, Julia P Gregory, Kimberly Gentile, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharmaceutical.

BHVN stock was sold by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Marshall Wace LLP, Eagle Asset Management Inc., Candriam Luxembourg S.C.A., UBS Asset Management Americas Inc., State Street Corp, UBS Group AG and Schonfeld Strategic Advisors LLC. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Elyse Stock, Eric Aguiar, John Tilton, Kimberly Gentile, Robert Berman and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.

BHVN stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, Point72 Asset Management L.P., Pictet Asset Management Ltd., Bluefin Trading LLC, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust and Rhenman & Partners Asset Management AB. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Gregory Bailey, James Engelhart, John W Childs and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.

Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BHVN stock can currently be purchased for approximately $42.50.

Biohaven Pharmaceutical has a market capitalization of $2.22 billion. The company earns $-240,920,000.00 in net income (profit) each year or ($10.91) on an earnings per share basis. Biohaven Pharmaceutical employs 63 workers across the globe.View Additional Information About Biohaven Pharmaceutical.

The official website for Biohaven Pharmaceutical is http://www.biohavenpharma.com/.

Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.